Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor vemurafenib with dacarbazine (DTIC) in patients with V600EBRAF-mutated melanoma.

@article{Chapman2011PhaseIR,
  title={Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor vemurafenib with dacarbazine (DTIC) in patients with V600EBRAF-mutated melanoma.},
  author={Paul B Chapman and A. H. W. Hauschild and Caroline Robert and James M. G. Larkin and John B A G Haanen and Antoni Ribas and David Hogg and Steven J. O'Day and Paolo Antonio Ascierto and Alessandro Testori and Paul C. Lorigan and Reinhard Dummer and Jeffrey A. Sosman and Claus Garbe and Richard W. J. Lee and Keith B. Nolop and Beverly A Nelson and Jeannie Whit-Shan Hou and Keith T. Flaherty and Grant Mcarthur},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2011},
  volume={29 18_suppl},
  pages={LBA4}
}
LBA4 Background: About 50% of melanomas have an activating V600EBRAF mutation which led to the hypothesis that inhibition of the mutated BRAF kinase may be of clinical benefit. Phase I and II trials with vemurafenib (previously PLX4032/RO5185426), an orally available inhibitor of oncogenic BRAF kinase, showed response rates (RR; CR+PR) >50% in V600EBRAF- mutated melanoma patients (pts). We conducted a phase III trial to determine if vemurafenib improved overall survival (OS) and progression… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 18 extracted citations

Similar Papers

Loading similar papers…